ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: FR-PO322

Peritoneal Dialysis in Pediatric ARPKD Patients

Session Information

Category: Genetic Diseases of the Kidney

  • 801 Cystic Kidney Diseases

Authors

  • Akarkach, Aziz, University Hospital Cologne, Cologne, Germany
  • Burgmaier, Kathrin, University Hospital Cologne, Cologne, Germany
  • Sander, Anja Christine, University of Heidelberg, Heidelberg, BW, Germany
  • Schaefer, Franz S., University of Heidelberg, Heidelberg, BW, Germany
  • Liebau, Max, University Hospital Cologne, Cologne, Germany

Group or Team Name

  • For IPPN consortium
Background

Autosomal recessive polycystic kidney disease (ARPKD) is associated with dialysis-requiring end stage renal disease in about 40-50% of patients during childhood and adolescence. Many ARPKD patients receive peritoneal dialysis (PD) but structured data on PD in pediatric ARPKD patients is missing.

Methods

We identified ARPKD patients in the international pediatric peritoneal dialysis network (IPPN) registry and compared their clinical courses and PD-specific parameters to two control groups suffering from other renal disorders (CAKUT, Congenital Nephrotic Syndrome). Cohorts were matched for age and time on dialysis.

Results

79 ARPKD patients were identified and matched to CNS (n=79) and CAKUT (n=158) patients. Mean age at inclusion into the IPPN registry was 4.38 years in the ARPKD group vs 4.33 years (CNS) and 4.40 years (CAKUT), respectively. Mean time on dialysis at inclusion was 1.01 years (ARPKD) vs. 0.77 years (CNS) and 1.00 years (CAKUT). Mean observation time within the frame of the registry was 14.6 months (ARPKD) vs. 11.2 months (CNS) and 13.2 months (CAKUT). There were no major differences in basic anthropometric data (height, weight, BMI) or general PD parameters (e.g. PD modality, applied PD fluids, fluid turnover per day, average glucose concentration), but ARPKD patients had regimes with lower overall fill volumes and more cycles than CNS- or CAKUT-patients. First longitudinal observations suggest that overall technique survival as well as the peritonitis rate in ARPKD children on PD do not show major differences compared to patients with other underlying disease entities.

Conclusion

Overall, children with ARPKD in this cohort do not show major dialysis-associated differences when compared to two age-matched pediatric PD control groups suggesting that PD can be applied in the same way as for children with other underlying renal disorders.

Funding

  • Private Foundation Support